+ 1 888 391 5441

China Human Vaccine Industry Report, 2018-2022

Synopsis

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination.

The lot release volume of human vaccines has remained at around 650 million doses over the past three years. China Food and Drug Administration (CFDA) approved the launch of 9-valent human papillomavirus vaccine (saccharomyces cerevisiae) and oral 5-valent reassortant rotavirus attenuated live vaccine (Vero cell) in the first half of 2018. The National Institutes for Food and Drug Control, Hubei Institute for Food and Drug Control, and Shanghai Institute for Food and Drug Control approved supply of 434.1 million doses (44 kinds of vaccines) to the market from January to September 2018.

With annual capacity of over one billion doses, more than forty vaccine manufacturers in China are capable of producing 63 kinds of vaccines for prevention of 34 sorts of infectious diseases. Among them, Chengdu Institute of Biological Products, Shanghai Institute of Biological Products, Lanzhou Institute of Biological Products, Wuhan Institute of Biological Products, Changchun Institute of Biological Products, Beijing Bio-Institute Biological Products, Changchun KEYGEN Biological Products, and Beijing Tiantan Biological Products (Beijing Tiantan Biological Products has no vaccine business after completion of asset restructuring in May 2017) under China National Biotech Group Co., Ltd. occupy half of the Chinese vaccine market. The subsidiaries under China National Biotech Group Co., Ltd. recorded lot release volume of 349.147 million doses in 2017 and 198.261 million doses in the first nine months of 2018, making up 53.1% and 45.7% of the country’s total amount, respectively.

In recent years, Chinese vaccine companies have spared no efforts in research and development to sharpen competitiveness. As yet, not a Chinese enterprise can produce HPV vaccines and 13-valent pneumonia vaccines, but local companies including Walvax Biotechnology and Shenzhen Kangtai Biological Products are developing such vaccines which are expected to be available soon.

With the implementation of two-child policy, the aging of population and the launch of new-type vaccines, China’s human vaccine industry will grow steadily in future, with the expected market size of RMB35.2 billion by 2022. Meanwhile, vaccine companies with richer capital and stronger R&D strength will give play to technological superiorities and scale effect, and raise their market share through capital operation and other means. In this sense, China’s vaccine industry tends to feature higher and higher concentration.

hina Human Vaccine Industry Report, 2018-2022 highlights the following:

  • China’s human vaccine industry (operating environment, status quo, market demand, distribution channels, market size, import and export, and competitive landscape);
  • Chinese human vaccine market segments (market demand, lot release volume and competitive landscape);
  • 22 human vaccine companies (operation, R&D and investment, development strategy, etc.) .
Why http://www.chinamarketresearchreports.com

China Human Vaccine Industry Report, 2018-2022

Published By :Research In China
Price

Related reports :

We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy